Bevacizumab and Pegylated Liposomal Doxorubicin as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer. A Multicenter, Single-Arm Phase II Trial.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab (Primary) ; Doxorubicin liposomal (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 28 Jun 2012 Biomarkers information updated
- 08 Jun 2012 Actual end date (1 Mar 2009) added as reported by ClinicalTrials.gov.
- 08 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.